New Colorectal Cancer Treatment Achieves Complete Remission in Young Patient

Mrinali Dhembla was 26 when doctors found stage 3 rectal cancer that had already spread to her spine. Four months and three infusions of immunotherapy later, her scans were clean. Her circulating tumor DNA — a molecular marker that tracks residual cancer in the bloodstream — dropped from 300 to zero [1]. By July 2025, she was declared cancer-free.

The story has the shape of a miracle. But the science behind it is more specific, more limited, and more complicated than headlines suggest. Understanding what happened to Dhembla, and what it means for the roughly 19,000 Americans under 50 who are diagnosed with colorectal cancer each year [4], requires separating the biology from the narrative.

What the Treatment Actually Is

Dhembla received a combination of nivolumab (brand name Opdivo) and ipilimumab (brand name Yervoy), two immune checkpoint inhibitors manufactured by Bristol Myers Squibb [1]. The FDA approved this combination for adults and pediatric patients 12 and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer in April 2025 [5].

Checkpoint inhibitors work by removing molecular "brakes" that cancer cells use to hide from the immune system. Nivolumab blocks a protein called PD-1 on the surface of T cells, while ipilimumab targets CTLA-4 — a different inhibitory receptor. Used together, they release the immune system to attack tumor cells on two fronts [16].

The key to Dhembla's response: genetic testing revealed she has Lynch syndrome, an inherited condition in which the body's DNA mismatch repair machinery is defective [1]. Tumors arising from Lynch syndrome accumulate far more mutations than typical cancers, which makes them highly visible to the immune system. As Dr. Nicholas Hornstein explained, patients with Lynch syndrome "have so many mutations in their cancer cells, it allows their immune system to recognize them, and they just need a little bit of a boost with immunotherapy to become effective at eradicating their tumors" [1].

This is not a universal cancer treatment. It is a targeted approach for a specific molecular subset.

The Trial Evidence: Remarkable, but Narrow

Dhembla's response is consistent with a body of clinical evidence that has been building since 2022, primarily from a phase 2 trial at Memorial Sloan Kettering Cancer Center (MSK) using a related checkpoint inhibitor, dostarlimab (brand name Jemperli, manufactured by GSK).

In results published in the New England Journal of Medicine in April 2025, the MSK trial enrolled 117 patients with early-stage dMMR solid tumors [2]. The findings:

• Among 49 patients with dMMR rectal cancer who completed treatment, 100% achieved a clinical complete response — meaning no detectable tumor on physical exam, imaging, or endoscopy. None required surgery, chemotherapy, or radiation [2].
• Among 54 patients with dMMR non-rectal cancers (including colon, gastroesophageal, and genitourinary tumors), 65% achieved clinical complete response [2].
• Across both cohorts, 82% of the 103 patients who completed treatment had a clinical complete response [2].
• At two years of follow-up, recurrence-free survival was 92% [2].

Source: New England Journal of Medicine

Data as of Apr 27, 2025CSV

These numbers are extraordinary by oncology standards. But they come with a critical caveat: every patient in the trial had dMMR tumors. Only about 15% of all colorectal cancers are dMMR or MSI-H [6] [16]. For the remaining 85% — tumors that are microsatellite stable (MSS) — checkpoint inhibitors have shown minimal efficacy, with objective response rates in the single digits [16].

The FDA granted dostarlimab Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer in December 2024, following a Fast Track designation in January 2023 [7]. A registrational trial called AZUR-1 is underway to confirm the phase 2 findings and support a broader approval [11]. But no timeline for full FDA approval has been announced.

What "Cancer-Free" Means — and Doesn't Mean

Dhembla's circulating tumor DNA (ctDNA) dropped to zero, and her scans and biopsies showed no evidence of disease [1]. In oncology, this combination of findings represents a strong signal: ctDNA is increasingly used as a molecular marker of minimal residual disease, and its absence correlates with favorable outcomes.

But "cancer-free" is not the same as "cured." Clinical complete response — the formal term — means no detectable disease by available methods at a point in time. It does not rule out microscopic cancer cells that fall below the detection threshold.

The MSK trial data illustrates this distinction. While 100% of dMMR rectal cancer patients achieved clinical complete response, four patients in the initial cohort experienced recurrence, bringing the two-year disease-free rate to 92% rather than 100% [2]. Some patients have maintained complete responses for five years, but the median follow-up remains relatively short at roughly 25 months [2].

Oncology has a history of premature victory declarations. The responsible interpretation of Dhembla's case is that she has had an excellent initial response to immunotherapy — one that is consistent with strong trial data for her tumor type — and will require ongoing surveillance to confirm that the response is durable.

An Epidemic in Young Adults

Dhembla's age — 26 at diagnosis — places her in a rapidly growing demographic. Colorectal cancer incidence in adults under 50 has been climbing at approximately 3% per year, even as rates have declined in older adults thanks to screening [4] [9].

Source: American Cancer Society / NCI SEER

Data as of Jan 15, 2026CSV

The numbers are stark: incidence in this age group rose from 8.6 per 100,000 in 1992 to an estimated 14.1 per 100,000 in 2023 [4]. One in five colorectal cancer diagnoses now occurs in someone under 55, up from about one in ten two decades ago [4]. Colorectal cancer has become the leading cause of cancer death in men under 50 and the second leading cause in women under 50 [17].

A Lancet Oncology analysis found the trend is not limited to the United States — early-onset colorectal cancer incidence is rising in 27 of 50 countries and territories examined [13].

Three in four colorectal cancers in adults younger than 50 are diagnosed at an advanced stage, partly because screening was not recommended for average-risk individuals under 45 until 2021 (when the U.S. Preventive Services Task Force lowered the recommended starting age from 50) [12].

What's Driving It?

The honest answer is that no single cause has been identified. Research has converged on several interrelated factors:

Diet: A Cleveland Clinic study identified diet-derived metabolites — particularly those associated with red and processed meat consumption — as a primary driver of young-onset colorectal cancer risk [14]. Diets high in processed food and low in fiber appear to increase risk.

Obesity: A meta-analysis found that each 5 kg/m² increase in body mass index is associated with a 5% increase in colorectal cancer risk [14]. Childhood and adolescent obesity rates have risen sharply in the same period that early-onset CRC has climbed.

Gut microbiome disruption: Dysbiosis — an imbalance in gut bacteria — has been linked to colorectal cancer promotion. Certain bacterial species appear to facilitate tumor growth, and factors like antibiotic use, diet, and sedentary behavior can shift the microbiome toward a pro-inflammatory state [14].

Sedentary lifestyle: Extended sitting time and reduced physical activity have been associated with higher early-onset CRC risk in multiple studies [9].

These factors likely interact: a high-processed-food diet alters the gut microbiome, which promotes chronic intestinal inflammation, which increases cancer risk. But the research remains correlational, and a definitive causal chain has not been established.

The Molecular Profile Question

Whether Dhembla's cancer has the molecular profile most common in young-onset cases is partly answered by her Lynch syndrome diagnosis. Lynch syndrome accounts for roughly 3-5% of all colorectal cancers but a higher fraction of early-onset cases. Her tumor is dMMR by definition, making her an ideal candidate for immunotherapy [1].

However, Lynch syndrome does not represent the majority of early-onset colorectal cancers. Many young-onset tumors are microsatellite stable and carry KRAS mutations — a profile for which immunotherapy alone is largely ineffective [16]. The most common molecular features of early-onset CRC include left-sided tumor location, more frequent signet ring cell histology, and a higher proportion of advanced-stage disease at diagnosis [12].

This is a crucial point that often gets lost in media coverage: Dhembla's favorable response is inextricable from her specific tumor biology. A 26-year-old with microsatellite-stable, KRAS-mutant colorectal cancer — a more common profile among young patients — would not be expected to respond similarly.

The Cost Barrier

The nivolumab-ipilimumab combination that Dhembla received carries a list price exceeding $250,000 per year [10]. The initial 12-week combination phase alone costs approximately $141,000, followed by ongoing nivolumab at roughly $12,500 per month [10].

Dostarlimab, the drug used in the MSK trial, costs approximately $11,000 per dose, with treatment typically involving multiple doses over six months or longer [15].

Bristol Myers Squibb and GSK both offer patient assistance programs, and some commercially insured patients may have out-of-pocket costs reduced substantially [10]. But the economics are particularly punishing for the young-adult demographic most affected by rising colorectal cancer rates:

• Adults under 35 are disproportionately uninsured or underinsured compared to older age groups.
• Many are on high-deductible health plans with significant cost-sharing requirements.
• Even with insurance, prior authorization requirements and off-label prescribing (in some clinical scenarios) can create access barriers.

For the estimated 19,000 Americans under 50 diagnosed with colorectal cancer annually, only the roughly 15% with dMMR/MSI-H tumors would be candidates for these immunotherapy regimens in the first place [4] [6]. That narrows the eligible pool to approximately 2,850 patients. How many of those can navigate the cost, insurance, and access hurdles to actually receive treatment at a specialized academic center is an open question — and almost certainly a fraction.

What Skeptics Say

Oncologists contacted for comment by multiple outlets have emphasized several points of caution:

Tumor biology, not just the drug: The extraordinary response rates in dMMR tumors may reflect the inherent immunogenicity of these cancers as much as the specific drug used. Multiple different checkpoint inhibitors — pembrolizumab, nivolumab, dostarlimab — have shown high response rates in dMMR cancers, suggesting the biology is doing much of the work [6] [16].

Selection effects: Patients who receive experimental immunotherapy protocols tend to be treated at major academic medical centers, are often younger and healthier than average cancer patients, and are selected through eligibility criteria that exclude those with complicating conditions. This makes trial results difficult to generalize to the broader population [2].

Spontaneous remission is not the explanation: While spontaneous cancer remission does occur (estimated at roughly 1 in 60,000 to 100,000 cases), the consistency of response across dozens of dMMR patients in the MSK trial — 100% in rectal cancer, 82% overall — rules this out as a plausible alternative explanation [2]. The treatment is working. The question is how broadly it applies.

Durability remains uncertain: Two-year follow-up data showing 92% recurrence-free survival is encouraging but not definitive [2]. Five-year data, the traditional benchmark in oncology for considering a cancer "cured," is available for only a small subset of the earliest-enrolled patients.

The Regulatory Road Ahead

The landscape for immunotherapy in dMMR colorectal cancer is advancing on multiple tracks:

• Nivolumab + ipilimumab: FDA-approved as of April 2025 for metastatic or unresectable MSI-H/dMMR colorectal cancer [5]. This is the regimen Dhembla received.
• Pembrolizumab: FDA-approved for first-line treatment of MSI-H/dMMR metastatic colorectal cancer since 2020, based on the KEYNOTE-177 trial of 307 patients [6].
• Dostarlimab: Granted Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer in December 2024 [7]. The AZUR-1 registrational trial is ongoing, and full approval — if the data hold — could come within two to three years [7] [11].

The critical gap: none of these approvals cover the use of immunotherapy as a replacement for surgery in early-stage dMMR rectal cancer, which is what the MSK trial demonstrated. That organ-preserving approach — treating with immunotherapy alone and skipping surgery entirely — remains available only through clinical trials or off-label use at select centers [2] [3].

For immunotherapy to become available to a broad patient population, rather than exclusively to those at institutions like MSK, MD Anderson, or the Mayo Clinic, the registrational trials will need to confirm the phase 2 findings, and FDA approval for the organ-sparing indication will need to follow.

A Research Field in Overdrive

The volume of published research on colorectal cancer immunotherapy has grown dramatically over the past decade, reflecting the intensity of scientific investment in this area.

Source: OpenAlex

Data as of Jan 1, 2026CSV

From roughly 1,000 papers in 2011 to more than 25,000 in 2024, the research base has expanded rapidly. This growth tracks with a series of clinical breakthroughs — the initial MSK case series in 2022, expanded trial results, and multiple FDA approvals — that have reshaped the treatment landscape for the subset of colorectal cancers that respond to immunotherapy [16].

The Bottom Line

Mrinali Dhembla's story is real, and the science behind it is solid — for patients whose tumors share her specific molecular profile. The MSK trial data, replicated across multiple checkpoint inhibitors and published in top-tier journals, demonstrates that dMMR colorectal cancers can respond to immunotherapy at rates that were unimaginable a decade ago [2].

But the reporting around cases like Dhembla's often collapses the distance between a single patient's outcome and a general advance against colorectal cancer. The treatment does not work for the 85% of colorectal cancers that are microsatellite stable [16]. It costs a quarter-million dollars a year at list price [10]. The organ-preserving approach is not yet FDA-approved outside of metastatic disease [7]. And the patients who need it most — young adults, increasingly diagnosed at advanced stages, often with inadequate insurance — face structural barriers to accessing it.

The advance is genuine. The question is whether the health system can deliver it equitably to the patients who stand to benefit — and whether the research community can extend similar results to the far larger population of colorectal cancer patients whose tumors do not respond to checkpoint blockade.